Zentalis Pharmaceuticals, Inc. (ZNTL) - Dilution Analysis

10-Q filing | 70.3M shares outstanding

8-K filing: The Company repurchased 7,500,000 shares of its common stock from Matrix Capital Master Fund, LP at a price of $1.33 per share on December 15, 2025. ($9.98M proceeds)

10-Q filing | 72.0M shares outstanding

10-Q filing | 71.7M shares outstanding

S-3 filing: The filing is an S-3 form for an at-the-market offering of common stock with an aggregate offering price of up to $75,000,000. The offering will be made from time to time through the sales agent, Leerink Partners LLC.

10-K filing | 71.1M shares outstanding

10-Q filing | 71.1M shares outstanding

10-Q filing | 71.0M shares outstanding

10-Q filing | 70.9M shares outstanding

10-K filing | 65.4M shares outstanding

10-Q filing | 70.6M shares outstanding

10-Q filing | 70.6M shares outstanding

8-K filing: Zentalis Pharmaceuticals, Inc. announced an offering of 11,032,656 shares of common stock at $22.66 per share, with expected net proceeds of approximately $235.5 million, to be used for clinical trials and general corporate purposes; the closing is expected on June 20, 2023. ($250.0M proceeds)

10-Q filing | 59.3M shares outstanding

10-K filing | 59.4M shares outstanding

10-Q filing | 56.8M shares outstanding

10-Q filing | 57.0M shares outstanding

8-K filing: Zentalis Pharmaceuticals, Inc. entered into an underwriting agreement for the offering, issuance, and sale of 10,330,000 shares of its common stock at $19.38 per share, with estimated net proceeds of approximately $188.5 million.

10-Q filing | 45.2M shares outstanding

8-K filing: Zentalis Pharmaceuticals, Inc. entered into a securities purchase agreement with Pfizer Inc. to sell 953,834 shares of the Company's common stock at a price of $26.21 per share, for gross proceeds of approximately $25.0 million. ($25.0M proceeds)

10-K filing | 42.7M shares outstanding

10-Q filing | 44.6M shares outstanding

10-Q filing | 40.7M shares outstanding

8-K filing: Zentalis Pharmaceuticals, Inc. completed a public offering of 3,565,000 shares of its common stock at a price of $48.50 per share, resulting in net proceeds of approximately $162.5 million. ($162.5M proceeds)

10-Q filing | 41.3M shares outstanding

S-3 filing: The filing relates to an at-the-market offering of common stock with an aggregate offering price of up to $200,000,000, through sales agent SVB Leerink LLC, to advance clinical development, fund research, and for working capital and other general corporate purposes.

10-K filing | 41.0M shares outstanding

10-Q filing | 40.6M shares outstanding

10-Q filing | 40.0M shares outstanding

S-1/A filing: This is an S-1/A filing. The company has granted the underwriters an option for a period of 30 days to purchase up to 562,500 additional shares of common stock.

10-Q filing | 35.9M shares outstanding

S-1/A filing: The filing relates to the issuance and sale of Series B and Series C convertible preferred units to accredited investors and qualified institutional buyers in reliance upon exemptions from registration requirements.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock by Zentalis Pharmaceuticals, Inc.